Table 2 Clinical characteristics of the subjects after stopping long-term NA therapy (longitudinal study)

N

26

65

Gender (M/F)

20/6

55/10

0.758

0.384^a

Age (years)

39 (25–60)

35 (18–49)

−2.063

0.039^b

HBV DNA (log₁₀ IU/ml)

UD

UD

–

–

ALT (× ULN)

0.488 (0.30–1.00)

0.519 (0.15–1.53)

−0.868

0.385^b

HBsAg (log₁₀ IU/ml)

2.995 (1.56–4.37)

2.810 (−2.00–4.14)

−1.805

0.071^b

Anti-HBc (log₁₀ IU/ml)

2.471 (1.51–3.64)

2.718 (1.21–3.86)

− 1.162

0.245^b

Week 4

HBV DNA (log₁₀ IU/ml)

0.00 (0.00–5.87)

0.00 (0.00–5.92)

−3.233

0.001^b

ALT (× ULN)

0.543 (0.25–2.08)

0.475 (0.20–1.55)

−0.545

0.586^b

HBsAg (log₁₀ IU/ml)

2.980 (1.47–4.37)

2.815 (−2.00–4.13)

−1.651

0.099^b

Anti-HBc (log₁₀ IU/ml)

2.585 (1.41–3.17)

2.793 (1.21–3.76)

−1.296

0.195^b

Week 12

HBV DNA (log₁₀ IU/ml)

3.98 (2.41–8.93)

2.39 (0.00–5.71)

−5.093

< 0.001^b

ALT (× ULN)

0.688 (0.30–18.20)

0.615 (0.15–1.98)

−1.456

0.145^b

HBsAg (log₁₀ IU/ml)

3.125 (2.12–.75)

2.760 (−1.70–4.14)

−2.705

0.007^b

Anti-HBc (log₁₀ IU/ml)

3.409 (1.77–4.71)

2.972 (1.21–4.43)

−1.555

0.12^b

Week 24

HBV DNA (log₁₀ IU/ml)

5.99 (4.30–8.93)

3.110 (0.00–5.73)

−5.432

< 0.001^b

ALT (× ULN)

1.074 (0.55–8.40)

0.550 (0.16–2.03)

−3.929

< 0.001^b

HBsAg (log₁₀ IU/ml)

3.575 (2.36–4.81)

2.680 (−2.00–4.19)

− 3.756

< 0.001^b

Anti-HBc (log₁₀ IU/ml)

3.634 (2.14–4.43)

3.344 (1.30–4.95)

−2.068

0.039^b

Week 48

HBV DNA (log₁₀ IU/ml)

5.66 (0.00–7.95)

2.880 (0.00–5.87)

−2.391

0.017^b

ALT (× ULN)

3.200 (1.45–7.90)

0.575 (0.18–1.80)

−2.879

0.004^b

HBsAg (log₁₀ IU/ml)

3.450 (2.77–3.45)

2.695 (−2.00–4.07)

−1.657

0.097^b

Anti-HBc (log₁₀ IU/ml)

4.395 (4.13–4.71)

3.378 (1.43–4.97)

−3.622

< 0.001^b

HBeAg (Positive:Negative)

17/9

46/19

0.253

0.615

ALT elevation ×ULN

3.53 (0–13.57)

6.20 (0–56.1)

−1.538

0.124

HBV DNA log₁₀ IU/ml

6.17(4.07–8.76)

6.33(3.32–9.15)

−0.371

0.711